Last reviewed · How we verify
Doxazosin mysylate GITS
Doxazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow, and also dilates blood vessels to lower blood pressure.
Doxazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow, and also dilates blood vessels to lower blood pressure. Used for Benign prostatic hyperplasia with lower urinary tract symptoms, Hypertension.
At a glance
| Generic name | Doxazosin mysylate GITS |
|---|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | Alpha-1 adrenergic receptor antagonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Urology |
| Phase | FDA-approved |
Mechanism of action
Doxazosin selectively blocks alpha-1 adrenergic receptors on smooth muscle cells in the prostate, bladder neck, and blood vessels. By antagonizing these receptors, it reduces smooth muscle tone and promotes relaxation, which decreases urinary obstruction in benign prostatic hyperplasia and reduces peripheral vascular resistance to lower blood pressure. The GITS (Gastrointestinal Therapeutic System) formulation provides extended-release delivery for once-daily dosing.
Approved indications
- Benign prostatic hyperplasia with lower urinary tract symptoms
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
- Asthenia
- Hypotension
- Syncope
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: